Phase 2 Study to Evaluate RPT193 in Adults With Moderate to Severe T2-high Asthma

• Status: Suspended
• Trial end date: 2025-08-01
• Target enrollment: 0
• Participant gender: All

Summary

Randomized, multi-center, double-blind, placebo-controlled, parallel group, proof of-concept study with RPT193 in subjects with T2-high, moderate-to-severe asthma who are partially controlled on medium or high doses of inhaled corticosteroids (ICS) in combination with long-acting beta 2 agonist (LABA).

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: RAPT Therapeutics, Inc.

Criteria

Inclusion Criteria:

• Physician diagnosis of asthma for ≥6 months

• Pre-bronchodilator FEV1 of >40% and <80%

• History of treatment with corticosteroid or hospitalization for worsening asthma

• Medium- or high-dose inhaled corticosteroid use

Exclusion Criteria:

• History of smoking/vaping

• History of severe COVID

• Serious and/or uncontrolled pulmonary, cardiac, immune system conditions

• Requires systemic oral or IV corticosteroids in the month prior to screening